| 1 | SDC4 levels | GCST90470559 | 106.32 |
| 2 | Mosaic chromosomal alteration of the Y chromosome | GCST90165289 | 103.26 |
| 3 | EDAR levels | GCST90469068 | 99.82 |
| 4 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 95.35 |
| 5 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 92.72 |
| 6 | Mean corpuscular haemoglobin | Blood count | UKBB00000447 | 89.41 |
| 7 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 86.71 |
| 8 | CCN2 levels | GCST90468588 | 85.97 |
| 9 | HSBP1 levels | GCST90469481 | 84.98 |
| 10 | Mean corpuscular volume | Blood count | UKBB00000449 | 81.10 |
| 11 | white blood cell count (WBC, maximum, inv-norm transformed) | GCST90476451 | 80.58 |
| 12 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 79.38 |
| 13 | Mean corpuscular hemoglobin | GCST90002390 | 78.97 |
| 14 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 78.89 |
| 15 | Bursitis (PheCode 726.3) | GCST90476240 | 77.97 |
| 16 | Platelet crit (UKB data field 30090) | GCST90468096 | 77.85 |
| 17 | SEMA4D/TREML2 ratio | GCST90315823 | 77.31 |
| 18 | FLT3LG levels | GCST90469250 | 76.07 |
| 19 | Mean corpuscular haemoglobin (UKB data field 30050) | GCST90468084 | 75.82 |
| 20 | EDAR/SDC4 ratio | GCST90314585 | 75.57 |
| 21 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475454 | 74.70 |
| 22 | Platelet distribution width | GCST90002401 | 73.84 |
| 23 | platelet count (maximum, inv-norm transformed) | GCST90476296 | 73.64 |
| 24 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 73.45 |
| 25 | Platelet distribution width (UKB data field 30110) | GCST90468097 | 73.04 |
| 26 | CPXM1/VEGFC ratio | GCST90314223 | 72.14 |
| 27 | DNM3 levels | GCST90469022 | 72.00 |
| 28 | DKK1/SDC4 ratio | GCST90314479 | 71.90 |
| 29 | Mean corpuscular hemoglobin | GCST004630 | 71.58 |
| 30 | Mean corpuscular volume | GCST90002392 | 70.81 |
| 31 | Mean reticulocyte volume | Blood count | UKBB00000451 | 69.98 |
| 32 | Platelet crit | Blood count | UKBB00000647 | 69.23 |
| 33 | Platelet count (UKB data field 30080) | GCST90468095 | 68.98 |
| 34 | DKK1/PDGFA ratio | GCST90314475 | 68.89 |
| 35 | ITGB1BP2/PTPN6 ratio | GCST90315218 | 68.81 |
| 36 | Platelet count during first trimester of pregnancy | GCST90302224 | 68.77 |
| 37 | CD244/EDAR ratio | GCST90313764 | 68.67 |
| 38 | MMP1/MMP3 ratio | GCST90315461 | 67.99 |
| 39 | EDAR/TNFSF12 ratio | GCST90314591 | 67.93 |
| 40 | Plateletcrit | GCST90002400 | 67.26 |
| 41 | Platelet distribution width | Blood count | UKBB00000648 | 67.00 |
| 42 | Mean corpuscular volume | GCST004602 | 65.81 |
| 43 | mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed) | GCST90475458 | 65.47 |
| 44 | Mean reticulocyte volume | GCST90002396 | 64.59 |
| 45 | MMP1 levels | GCST90469919 | 64.48 |
| 46 | Platelet distribution width | GCST004616 | 64.20 |
| 47 | CCL28/PDGFB ratio | GCST90313695 | 64.19 |
| 48 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 63.68 |
| 49 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 63.60 |
| 50 | Platelet count | GCST90002402 | 63.43 |
| 51 | platelet count (mean, inv-norm transformed) | GCST90476299 | 63.17 |
| 52 | MMP1/SERPINB6 ratio | GCST90315462 | 63.16 |
| 53 | Platelet count | Blood count | UKBB00000646 | 62.25 |
| 54 | Operation code - bunion/hallus valgus surgery | Operations | UKBB00000551 | 62.25 |
| 55 | EDAR/TREML2 ratio | GCST90314592 | 62.16 |
| 56 | DNAJC6 levels | GCST90469017 | 61.93 |
| 57 | mean corpuscular hemoglobin concentration (MCHC, minimum, inv-norm transformed) | GCST90475462 | 61.53 |
| 58 | CRYGD levels | GCST90468876 | 60.81 |
| 59 | sodium (minimum, inv-norm transformed) | GCST90476397 | 60.32 |
| 60 | TNFRSF10C levels | GCST90470901 | 60.09 |
| 61 | Platelet count | GCST90278640 | 59.93 |
| 62 | CST3/DEFA1_DEFA1B ratio | GCST90314291 | 59.57 |
| 63 | PDGFA levels | GCST90470188 | 56.15 |
| 64 | DKK1 levels | GCST90468997 | 56.03 |
| 65 | red blood cell count (RBC, maximum, inv-norm transformed) | GCST90476345 | 55.55 |
| 66 | HBEGF levels | GCST90469433 | 55.32 |
| 67 | Mean sphered cell volume | Blood count | UKBB00000452 | 54.54 |
| 68 | EDAR/SPARC ratio | GCST90314588 | 54.51 |
| 69 | ITGB1BP2/MED18 ratio | GCST90315213 | 54.26 |
| 70 | CDKN2D/ITGB1BP2 ratio | GCST90313987 | 54.23 |
| 71 | ENO2/ITGB1BP2 ratio | GCST90314661 | 54.16 |
| 72 | CPXM1/SPARC ratio | GCST90314222 | 54.03 |
| 73 | Low back pain | FING00000730 | 53.99 |
| 74 | Osteoarthritis, localized (PheCode 740.1) | GCST90476254 | 53.81 |
| 75 | Mean corpuscular volume | GCST90002335 | 53.62 |
| 76 | Prescriptions - gliclazide | sulfonylurea,diabetes | UKBB00000684 | 53.43 |
| 77 | KIFBP/LYN ratio | GCST90315246 | 53.42 |
| 78 | EDAR/PSRC1 ratio | GCST90314584 | 53.27 |
| 79 | Biological Grandparent (paternal): Diabetes / Sugar | GCST90475549 | 53.12 |
| 80 | Number of non-cancer illnesses (standard GWA) | GCST90267290 | 53.11 |
| 81 | KIFBP/TACC3 ratio | GCST90315249 | 52.87 |
| 82 | Red blood cell count | GCST004601 | 52.79 |
| 83 | CCN2/EDAR ratio | GCST90313711 | 52.79 |
| 84 | GALNT5 levels | GCST90469298 | 52.73 |
| 85 | Red blood cell erythrocyte count (UKB data field 30010) | GCST90468098 | 52.23 |
| 86 | Mean sphered cell volume (UKB data field 30270) | GCST90468089 | 52.13 |
| 87 | PDGFA/VEGFC ratio | GCST90315622 | 51.61 |
| 88 | DAPP1/PMVK ratio | GCST90314396 | 51.59 |
| 89 | CPXM1/MDK ratio | GCST90314221 | 51.44 |
| 90 | VEGFA levels | GCST90471034 | 51.42 |
| 91 | APP/CD40LG ratio | GCST90313319 | 51.29 |
| 92 | CRYBB1 levels | GCST90468874 | 51.17 |
| 93 | Red blood cell count | GCST90018751 | 51.06 |
| 94 | Non-cancer illness code, self-reported - type 2 diabetes | Medical conditions | UKBB00000522 | 50.88 |
| 95 | platelet count (minimum, inv-norm transformed) | GCST90476302 | 50.74 |
| 96 | Mean corpuscular volume | GCST90018746 | 50.74 |
| 97 | CCL28 levels | GCST90468580 | 50.59 |
| 98 | Insomnia complaints | GCST004695 | 50.58 |
| 99 | CD36 levels | GCST90468627 | 50.48 |
| 100 | white blood cell count (WBC, mean, inv-norm transformed) | GCST90476454 | 50.37 |
| 101 | PDGFB/SDC4 ratio | GCST90315626 | 49.91 |
| 102 | CXCL6 levels | GCST90468933 | 49.76 |
| 103 | Basophil count | GCST90002293 | 49.31 |
| 104 | PGLYRP1 levels | GCST90470219 | 49.11 |
| 105 | FADD/MGLL ratio | GCST90314768 | 48.82 |
| 106 | CXCL11 levels | GCST90468924 | 48.76 |
| 107 | Platelet count during second trimester of pregnancy | GCST90302225 | 48.71 |
| 108 | Telomere length (principal component 1) | GCST90435144 | 48.43 |
| 109 | Red blood cell count | GCST90002364 | 48.04 |
| 110 | FADD/PTPN6 ratio | GCST90314775 | 47.80 |
| 111 | COCH levels | GCST90468810 | 47.72 |
| 112 | CAPS levels | GCST90468539 | 47.53 |
| 113 | Plateletcrit | GCST004607 | 47.41 |
| 114 | MZB1 levels | GCST90469987 | 47.25 |
| 115 | F2R/ITGB1BP2 ratio | GCST90314731 | 47.22 |
| 116 | CDKN2D/MANF ratio | GCST90313989 | 47.01 |
| 117 | COL2A1 levels | GCST90468816 | 47.01 |
| 118 | Mean spheric corpuscular volume | GCST90002397 | 46.40 |
| 119 | APP/NID1 ratio | GCST90313326 | 46.36 |
| 120 | SDC4/SERPINE1 ratio | GCST90315819 | 46.19 |
| 121 | SEMA4D levels | GCST90470573 | 46.09 |
| 122 | CCN2/DKK1 ratio | GCST90313710 | 45.95 |
| 123 | Alcohol dependence | FING00000050 | 45.79 |
| 124 | CD84/TREML2 ratio | GCST90313919 | 45.77 |
| 125 | HBEGF/SDC4 ratio | GCST90315037 | 45.69 |
| 126 | ABHD14B/APRT ratio | GCST90313137 | 45.38 |
| 127 | CXCL12/TIMP3 ratio | GCST90314338 | 45.04 |
| 128 | GRAP2/MAP4K5 ratio | GCST90314982 | 44.92 |
| 129 | Insomnia complaints | GCST006488 | 44.76 |
| 130 | CDKN2D/TACC3 ratio | GCST90313992 | 44.33 |
| 131 | FUT8/PDGFA ratio | GCST90314890 | 44.28 |
| 132 | CCL2 levels | GCST90468581 | 44.20 |
| 133 | Red blood cell count | GCST90002403 | 43.86 |
| 134 | Platelet count | GCST004603 | 43.28 |
| 135 | Lower back pain or/and sciatica | FING00000731 | 43.17 |
| 136 | PIK3AP1 levels | GCST90470233 | 43.14 |
| 137 | BTC levels | GCST90468476 | 42.92 |
| 138 | CNTNAP2/DPP10 ratio | GCST90314167 | 42.85 |
| 139 | Dorsalgia | FING00000472 | 42.55 |
| 140 | MAX/STK24 ratio | GCST90315404 | 42.51 |
| 141 | Basophil count | GCST90018726 | 42.06 |
| 142 | SPARC/TACC3 ratio | GCST90315872 | 41.66 |
| 143 | Platelet count during third trimester of pregnancy | GCST90302226 | 41.65 |
| 144 | CLEC1B/NSFL1C ratio | GCST90314099 | 41.39 |
| 145 | Subclinical hypothyroidism in pregnancy | GCST90435197 | 41.29 |
| 146 | MAX/TDRKH ratio | GCST90315406 | 41.28 |
| 147 | ANGPT1/CPXM1 ratio | GCST90313262 | 40.87 |
| 148 | CA4/TNFSF12 ratio | GCST90313589 | 40.83 |
| 149 | IDP dMRI ProbtrackX ISOVF ifo l | GCST90004537 | 40.81 |
| 150 | Age at first sexual intercourse | GCST90000046 | 40.79 |
| 151 | SNAP23/ZBTB16 ratio | GCST90315858 | 40.56 |
| 152 | CLEC1B/RWDD1 ratio | GCST90314102 | 40.40 |
| 153 | Pain in limb (PheCode 773) | GCST90476270 | 40.32 |
| 154 | Mean corpuscular hemoglobin | GCST90018744 | 40.28 |
| 155 | PDGFA/SCARF1 ratio | GCST90315617 | 40.12 |
| 156 | CXCL3/CXCL5 ratio | GCST90314344 | 40.09 |
| 157 | White blood cell count | GCST90018758 | 40.00 |
| 158 | red blood cell count (RBC, minimum, inv-norm transformed) | GCST90476353 | 39.99 |
| 159 | Red blood cell (erythrocyte) count | Blood count | UKBB00000747 | 39.88 |
| 160 | AXIN1/MAP2K6 ratio | GCST90313413 | 39.83 |
| 161 | F9/RARRES2 ratio | GCST90314749 | 39.61 |
| 162 | Heart failure, strict | FING00000606 | 39.45 |
| 163 | CCL17 levels | GCST90468569 | 39.29 |
| 164 | Platelet count | GCST90018749 | 39.28 |
| 165 | REST UKBBICA NODEamps25 0014 | GCST90385497 | 39.24 |
| 166 | CDKN1A/TACC3 ratio | GCST90313975 | 39.23 |
| 167 | CPXM1/LGMN ratio | GCST90314220 | 39.21 |
| 168 | Clonal haematopoiesis of indeterminate potential (DNMT3A mutation) | GCST90165271 | 38.95 |
| 169 | Number of operations, self-reported | Operations | UKBB00000539 | 38.93 |
| 170 | Pain (PheCode 338) | GCST90475836 | 38.65 |
| 171 | CCL17/GRK5 ratio | GCST90313687 | 38.44 |
| 172 | Prescriptions - sulfonylurea|diabetes | UKBB00000703 | 38.42 |
| 173 | ENO2/RWDD1 ratio | GCST90314667 | 38.36 |
| 174 | PPCDC/RWDD1 ratio | GCST90315704 | 38.24 |
| 175 | CXCL6/DFFA ratio | GCST90314357 | 38.21 |
| 176 | CLEC1B/VTA1 ratio | GCST90314107 | 38.20 |
| 177 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476349 | 38.11 |
| 178 | CRADD/FADD ratio | GCST90314237 | 38.08 |
| 179 | CCL5/TACC3 ratio | GCST90313707 | 37.95 |
| 180 | VEGFC levels | GCST90471036 | 37.88 |
| 181 | TRIAP1 levels | GCST90470963 | 37.87 |
| 182 | ANXA3/BID ratio | GCST90313279 | 37.70 |
| 183 | CXCL5 levels | GCST90468932 | 37.52 |
| 184 | CD63/EDAR ratio | GCST90313864 | 37.42 |
| 185 | ATP5IF1 levels | GCST90468392 | 37.42 |
| 186 | CLEC1B/LGALS8 ratio | GCST90314096 | 37.42 |
| 187 | CCN2/VEGFC ratio | GCST90313719 | 37.33 |
| 188 | Anterior diffusion tensor imaging along the perivascular space index | GCST90455543 | 37.21 |
| 189 | F-caffeinated/sweet liking (derived food-liking factor) | GCST90094720 | 37.19 |
| 190 | DARS1 levels | GCST90468947 | 37.12 |
| 191 | ARHGAP1 levels | GCST90468352 | 37.09 |
| 192 | neutrophil (absolute count, maximum, inv-norm transformed) | GCST90475526 | 37.00 |
| 193 | AXL/CD163 ratio | GCST90313418 | 36.93 |
| 194 | MAP3K5/ZBTB16 ratio | GCST90315380 | 36.79 |
| 195 | BDNF levels | GCST90468437 | 36.76 |
| 196 | GP5 levels | GCST90469383 | 36.59 |
| 197 | SDC4/SELP ratio | GCST90315817 | 36.54 |
| 198 | Other and unspecified tonsillitis | FING00000954 | 36.39 |
| 199 | DAG1/F2R ratio | GCST90314374 | 35.89 |
| 200 | Tea difference liking | GCST90094855 | 35.79 |
| 201 | IPCEF1/SMAD1 ratio | GCST90315185 | 35.77 |
| 202 | CRELD2/F2R ratio | GCST90314254 | 35.74 |
| 203 | JAM3 levels | GCST90469660 | 35.74 |
| 204 | Right-hemisphere default mode network to amygdala white-matter structural connectivity | GCST90302849 | 35.64 |
| 205 | Right-hemisphere somatomotor network to pallidum white-matter structural connectivity | GCST90302797 | 35.64 |
| 206 | ITGB1BP2 levels | GCST90469642 | 35.52 |
| 207 | Methods of admission to hospital (recoded) - Emergency admission: A&E | Summary Administration | UKBB00000464 | 35.51 |
| 208 | ANGPT1/CCN2 ratio | GCST90313261 | 35.32 |
| 209 | neutrophil (absolute count, mean, inv-norm transformed) | GCST90475529 | 35.26 |
| 210 | Other joint disorders | FING00001064 | 35.25 |
| 211 | Platelet count | GCST90002358 | 35.17 |
| 212 | CRISP3 levels | GCST90468866 | 35.16 |
| 213 | FGF2/HBEGF ratio | GCST90314811 | 35.14 |
| 214 | LCN2 levels | GCST90469747 | 34.82 |
| 215 | CD40 levels | GCST90468633 | 34.78 |
| 216 | CXCL5/SDC4 ratio | GCST90314353 | 34.77 |
| 217 | DEFA1 or DEFA1B levels | GCST90468979 | 34.74 |
| 218 | TIMP3 levels | GCST90470871 | 34.65 |
| 219 | White blood cell count (basophil) | GCST004618 | 34.63 |
| 220 | Sodium (mean, inv-norm transformed) | GCST90476395 | 34.55 |
| 221 | SMTN levels | GCST90470689 | 34.49 |
| 222 | CXCL5/EDAR ratio | GCST90314349 | 34.43 |
| 223 | CPXM1 levels | GCST90468849 | 34.32 |
| 224 | FADD/LACTB2 ratio | GCST90314767 | 34.20 |
| 225 | SMAD1 levels | GCST90470675 | 34.09 |
| 226 | Right-hemisphere somatomotor network to thalamus white-matter structural connectivity | GCST90302794 | 34.07 |
| 227 | Arthropathy NOS | musculoskeletal | UKBB00000051 | 34.05 |
| 228 | Basophil percentage of white cells | GCST004631 | 33.98 |
| 229 | CLEC1B/SNAP29 ratio | GCST90314103 | 33.91 |
| 230 | ANGPT1/APP ratio | GCST90313260 | 33.90 |
| 231 | TGFB1 levels | GCST90470843 | 33.82 |
| 232 | CYB5R2 levels | GCST90468937 | 33.59 |
| 233 | TPD52L2 levels | GCST90470942 | 33.40 |
| 234 | Tea with sugar liking | GCST90094857 | 33.33 |
| 235 | DAG1 levels | GCST90468943 | 33.26 |
| 236 | CPXM1/DKK1 ratio | GCST90314218 | 33.04 |
| 237 | EDAR/PRDX5 ratio | GCST90314583 | 33.02 |
| 238 | AZU1/RNASE3 ratio | GCST90313428 | 33.00 |
| 239 | NUCB2/TRIAP1 ratio | GCST90315577 | 32.89 |
| 240 | DKK1/SERPINE1 ratio | GCST90314480 | 32.73 |
| 241 | PDGFB levels | GCST90470189 | 32.67 |
| 242 | CXCL5/SERPINE1 ratio | GCST90314354 | 32.67 |
| 243 | EGFL7 levels | GCST90469083 | 32.66 |
| 244 | PPP1R2/TMSB10 ratio | GCST90315721 | 32.63 |
| 245 | PLIN3/VSIR ratio | GCST90315679 | 32.58 |
| 246 | PDGFA/SPARC ratio | GCST90315620 | 32.55 |
| 247 | FLT3/FLT3LG ratio | GCST90314859 | 32.39 |
| 248 | 1-linoleoyl-GPI (18:2) levels | GCST90199821 | 32.38 |
| 249 | Mean platelet (thrombocyte) volume | Blood count | UKBB00000450 | 32.33 |
| 250 | ATP5IF1/DECR1 ratio | GCST90313382 | 32.24 |
| 251 | Taking other prescription medications | Medication | UKBB00000813 | 32.21 |
| 252 | FCRL1/TREML2 ratio | GCST90314797 | 32.21 |
| 253 | Abdominal pain | symptoms | UKBB00000003 | 32.18 |
| 254 | Depression medications | FING00000399 | 31.94 |
| 255 | ADGRE5/SEMA7A ratio | GCST90313183 | 31.70 |
| 256 | Immature reticulocyte fraction | Blood count | UKBB00000355 | 31.69 |
| 257 | DNPH1/PDGFB ratio | GCST90314527 | 31.66 |
| 258 | ENO2/MGLL ratio | GCST90314663 | 31.66 |
| 259 | ANXA3/ENO2 ratio | GCST90313281 | 31.58 |
| 260 | CXCL8 levels | GCST90468934 | 31.56 |
| 261 | MPI/TACC3 ratio | GCST90315491 | 31.56 |
| 262 | Age at first sexual intercourse | GCST90000047 | 31.52 |
| 263 | SERPINH1 levels | GCST90470601 | 31.52 |
| 264 | SERPINB9 levels | GCST90470593 | 31.50 |
| 265 | Arthropathies | FING00000107 | 31.50 |
| 266 | MECR levels | GCST90469879 | 31.49 |
| 267 | ABHD14B/CRADD ratio | GCST90313141 | 31.44 |
| 268 | TNFRSF14 levels | GCST90470907 | 31.44 |
| 269 | PDGFA/SERPINE1 ratio | GCST90315618 | 31.30 |
| 270 | TNFRSF13C/TNFSF13B ratio | GCST90315934 | 31.29 |
| 271 | SCARF1 levels | GCST90470536 | 31.28 |
| 272 | Mean reticulocyte volume | GCST90025975 | 31.26 |
| 273 | Peak expiratory flow (PEF) | Spirometry | UKBB00000638 | 31.21 |
| 274 | Blood cell traits latent factor 18 (platelet) | GCST90559260 | 31.19 |
| 275 | CFC1 levels | GCST90468724 | 31.17 |
| 276 | APP/CCL28 ratio | GCST90313317 | 31.13 |
| 277 | BMI and adiposity (confirmatory factor analysis Factor 7) | GCST90309342 | 31.00 |
| 278 | NID1/TIMP3 ratio | GCST90315543 | 30.90 |
| 279 | GP1BA/HBEGF ratio | GCST90314956 | 30.84 |
| 280 | Obstructive chronic bronchitis (PheCode 496.21) | GCST90476030 | 30.84 |
| 281 | Phosphatidylethanolamine_40:6_[M-H]1- levels | GCST90060365 | 30.82 |
| 282 | Other arthropathies | musculoskeletal | UKBB00000601 | 30.80 |
| 283 | Prescriptions - ACE inhibitor|anti-hypertensive | UKBB00000657 | 30.74 |
| 284 | ATP5IF1/LYN ratio | GCST90313389 | 30.70 |
| 285 | SERPINE2 levels | GCST90470597 | 30.50 |
| 286 | ATP5IF1/METAP1D ratio | GCST90313391 | 30.45 |
| 287 | LYN/YES1 ratio | GCST90315351 | 30.43 |
| 288 | NTF4 levels | GCST90470095 | 30.41 |
| 289 | PDAP1 levels | GCST90470179 | 30.28 |
| 290 | MAP2 levels | GCST90469853 | 30.28 |
| 291 | SNAP29/TJAP1 ratio | GCST90315861 | 30.28 |
| 292 | Attention deficit hyperactivity disorder | GCST90568441 | 30.27 |
| 293 | Principal component-derived dietary pattern 45 | GCST90133050 | 30.26 |
| 294 | CALCOCO1/MAP3K5 ratio | GCST90313605 | 30.24 |
| 295 | CXCL5/SPARC ratio | GCST90314355 | 30.19 |
| 296 | BAX/MAX ratio | GCST90313466 | 30.14 |
| 297 | ATP5IF1/HSPA1A ratio | GCST90313388 | 30.08 |
| 298 | Chronic diseases of tonsils and adenoids | FING00000283 | 30.08 |
| 299 | PVALB levels | GCST90470393 | 30.07 |
| 300 | Principal component-derived dietary pattern 2 | GCST90133007 | 30.04 |
| 301 | Paracetamol of NSAID medication | FING00001145 | 30.04 |
| 302 | Salt added to food | Diet | UKBB00000762 | 29.92 |
| 303 | TFPI2 levels | GCST90470838 | 29.91 |
| 304 | Hematocrit | GCST90018740 | 29.82 |
| 305 | HTRA2/TRIAP1 ratio | GCST90315099 | 29.79 |
| 306 | Gonarthrosis, primary, with knee surgery | FING00000586 | 29.78 |
| 307 | DEFA1_DEFA1B/PTGDS ratio | GCST90314455 | 29.67 |
| 308 | 1-ribosyl-imidazoleacetate levels | GCST90199815 | 29.66 |
| 309 | Educational attainment | GCST003496 | 29.62 |
| 310 | Immature reticulocyte fraction (UKB data field 30280) | GCST90468079 | 29.61 |
| 311 | CD40LG levels | GCST90468632 | 29.54 |
| 312 | FHIT levels | GCST90469238 | 29.54 |
| 313 | Blood cell traits latent factor 22 (white cell) | GCST90559264 | 29.34 |
| 314 | Alcohol use disorder, ICD-based | FING00000052 | 29.32 |
| 315 | Clonal haematopoiesis of indeterminate potential (with or without mosaic chromosomal alteration) | GCST90165267 | 29.29 |
| 316 | Drive faster than motorway speed limit | Physical activity | UKBB00000194 | 29.29 |
| 317 | CCL17/PDGFB ratio | GCST90313688 | 29.19 |
| 318 | TREML2 levels | GCST90470962 | 29.18 |
| 319 | CCL17/F2R ratio | GCST90313686 | 29.05 |
| 320 | Age first had sexual intercourse | Sexual factors | UKBB00000014 | 29.05 |
| 321 | DNPH1/NSFL1C ratio | GCST90314526 | 29.03 |
| 322 | CLEC1B levels | GCST90468768 | 29.01 |
| 323 | GALNT3 levels | GCST90469297 | 28.97 |
| 324 | mean platelet volume (MPV, maximum, inv-norm transformed) | GCST90475517 | 28.96 |
| 325 | ENO2/PLXNA4 ratio | GCST90314665 | 28.95 |
| 326 | SNAP23/SNAP29 ratio | GCST90315855 | 28.85 |
| 327 | GIPC3 levels | GCST90469348 | 28.76 |
| 328 | F9/FURIN ratio | GCST90314747 | 28.73 |
| 329 | EBAG9/TBCB ratio | GCST90314567 | 28.70 |
| 330 | Leisure screen time | GCST90104339 | 28.68 |
| 331 | OSCAR levels | GCST90470131 | 28.58 |
| 332 | In your lifetime, have you smoked a total of at least 100 cigarettes? | GCST90476387 | 28.56 |
| 333 | ERP29 levels | GCST90088843 | 28.55 |
| 334 | IDP dMRI TBSS OD Genu of corpus callosum | GCST90004404 | 28.48 |
| 335 | Treatment/medication code - ramipril | Medications | UKBB00000856 | 28.41 |
| 336 | Shortness of breath (PheCode 512.7) | GCST90476040 | 28.38 |
| 337 | Heart failure and bmi 25plus | FING00000603 | 28.31 |
| 338 | CLEC1B/GP1BA ratio | GCST90314091 | 28.31 |
| 339 | CD84 levels | GCST90468653 | 28.23 |
| 340 | MAVS/ZBTB16 ratio | GCST90315401 | 28.21 |
| 341 | Whole body fat free mass (UKB data field 23101) | GCST90428120 | 28.18 |
| 342 | ARHGAP1/SPARC ratio | GCST90313344 | 28.17 |
| 343 | Osteoarthrosis (PheCode 740) | GCST90476253 | 28.14 |
| 344 | LAT/LYN ratio | GCST90315283 | 28.12 |
| 345 | SELP levels | GCST90470569 | 28.09 |
| 346 | PRG3 levels | GCST90470323 | 28.08 |
| 347 | SPRY2 levels | GCST90470738 | 27.97 |
| 348 | white blood cell count (WBC, minimum, inv-norm transformed) | GCST90476457 | 27.95 |
| 349 | Mean corpuscular hemoglobin concentration | GCST90002328 | 27.92 |
| 350 | EDAR/F2R ratio | GCST90314577 | 27.88 |
| 351 | White blood cell count | GCST90002375 | 27.76 |
| 352 | AXIN1/GOPC ratio | GCST90313407 | 27.75 |
| 353 | ITGB5/VSIR ratio | GCST90315235 | 27.75 |
| 354 | CCN3/PGF ratio | GCST90313722 | 27.71 |
| 355 | ANG/RARRES2 ratio | GCST90313271 | 27.67 |
| 356 | Medication use (adrenergics, inhalants) | GCST90018779 | 27.62 |
| 357 | MPHOSPH8 levels | GCST90469934 | 27.59 |
| 358 | Immature fraction of reticulocytes | GCST004628 | 27.55 |
| 359 | CLEC1B/PPP1R2 ratio | GCST90314101 | 27.52 |
| 360 | F2R/TNFRSF14 ratio | GCST90314739 | 27.44 |
| 361 | FHIT/PMVK ratio | GCST90314822 | 27.43 |
| 362 | Gestational thrombocytopenia | GCST90302234 | 27.34 |
| 363 | APP/HBEGF ratio | GCST90313324 | 27.34 |
| 364 | CEACAM8/PGLYRP1 ratio | GCST90314003 | 27.30 |
| 365 | SPARC levels | GCST90470718 | 27.30 |
| 366 | ERBIN/LYN ratio | GCST90314694 | 27.21 |
| 367 | FGFBP3 levels | GCST90469232 | 27.20 |
| 368 | TOMM20 levels | GCST90470931 | 27.15 |
| 369 | ENO2/SULT1A1 ratio | GCST90314669 | 27.14 |
| 370 | CCN2/TPP1 ratio | GCST90313718 | 27.11 |
| 371 | Other diseases of upper respiratory tract | FING00001012 | 27.05 |
| 372 | AXIN1/BACH1 ratio | GCST90313400 | 27.02 |
| 373 | SIGLEC8 levels | GCST90470636 | 27.02 |
| 374 | Mean platelet volume | GCST90002395 | 26.96 |
| 375 | SERPINB6 levels | GCST90470591 | 26.92 |
| 376 | Crohn's disease | GCST90446793 | 26.92 |
| 377 | CXCL10/CXCL11 ratio | GCST90314330 | 26.87 |
| 378 | monocyte (absolute count, maximum, inv-norm transformed) | GCST90475499 | 26.86 |
| 379 | Mean corpuscular hemoglobin | GCST90002323 | 26.83 |
| 380 | Hypothyroidism, drug reimbursement | FING00000655 | 26.81 |
| 381 | MED18/TACC3 ratio | GCST90315414 | 26.74 |
| 382 | CXCL5/PPIB ratio | GCST90314352 | 26.72 |
| 383 | NID1/SORT1 ratio | GCST90315542 | 26.70 |
| 384 | Nonspecific chest pain (PheCode 418) | GCST90475947 | 26.69 |
| 385 | EBAG9/EDAR ratio | GCST90314563 | 26.67 |
| 386 | CERT/MAX ratio | GCST90314028 | 26.62 |
| 387 | SRC/TBL1X ratio | GCST90315884 | 26.61 |
| 388 | APP/DAG1 ratio | GCST90313320 | 26.57 |
| 389 | Non-ischemic cardiomyopathy | FING00000873 | 26.48 |
| 390 | Sleep apnoea | FING00001309 | 26.45 |
| 391 | HTRA2/SNAP29 ratio | GCST90315098 | 26.37 |
| 392 | APP levels | GCST90468344 | 26.34 |
| 393 | Vanillylmandelate (VMA) levels | GCST90200309 | 26.28 |
| 394 | Pulmonary heart disease (PheCode 415) | GCST90475942 | 26.26 |
| 395 | MGLL levels | GCST90469901 | 26.23 |
| 396 | Mean platelet volume during second trimester of pregnancy | GCST90302230 | 26.15 |
| 397 | Preterm labour and delivery | FING00001209 | 26.10 |
| 398 | GALNT10/TNFSF12 ratio | GCST90314916 | 26.07 |
| 399 | EDAR/F11R ratio | GCST90314576 | 26.04 |
| 400 | MDK levels | GCST90469877 | 25.98 |
| 401 | LYN/TACC3 ratio | GCST90315350 | 25.95 |
| 402 | Mean platelet volume | GCST004599 | 25.95 |
| 403 | PDGFB/SPINT2 ratio | GCST90315629 | 25.88 |
| 404 | Mean platelet volume during first trimester of pregnancy | GCST90302229 | 25.87 |
| 405 | NID2 levels | GCST90470048 | 25.83 |
| 406 | SELL levels | GCST90470567 | 25.81 |
| 407 | SPINT2 levels | GCST90470728 | 25.76 |
| 408 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T216 | ECGA000216 | 25.64 |
| 409 | Other symptoms of respiratory system (PheCode 512) | GCST90476039 | 25.63 |
| 410 | EBAG9/MITD1 ratio | GCST90314566 | 25.61 |
| 411 | Blood cell traits latent factor 8 (white cell) | GCST90559250 | 25.60 |
| 412 | SERPINI1 levels | GCST90470602 | 25.59 |
| 413 | MCFD2/VSIR ratio | GCST90315411 | 25.53 |
| 414 | Codeine or tramadol medication | FING00000311 | 25.52 |
| 415 | METAP1D/VASH1 ratio | GCST90315429 | 25.51 |
| 416 | Pain in joint (PheCode 745) | GCST90476262 | 25.47 |
| 417 | PLCB2 levels | GCST90470255 | 25.44 |
| 418 | FABP5/PPCDC ratio | GCST90314763 | 25.44 |
| 419 | Types of transport used (excluding work) - Public transport | Physical activity | UKBB00000878 | 25.42 |
| 420 | CEACAM8/RNASE3 ratio | GCST90314004 | 25.39 |
| 421 | IDP dMRI ProbtrackX ISOVF ifo r | GCST90004538 | 25.34 |
| 422 | MATN3 levels | GCST90469865 | 25.34 |
| 423 | SLAMF8 levels | GCST90470652 | 25.28 |
| 424 | GOLGA3 levels | GCST90469375 | 25.28 |
| 425 | Own or rent accommodation lived in - Rent - from local authority, local council, housing association | Household | UKBB00000624 | 25.24 |
| 426 | SERPINE1 levels | GCST90470596 | 25.22 |
| 427 | BMP6 levels | GCST90468454 | 25.17 |
| 428 | White blood cell (leukocyte) count | Blood count | UKBB00000913 | 25.16 |
| 429 | Spondylosis | FING00001327 | 25.05 |
| 430 | FGF2 levels | GCST90469224 | 25.04 |
| 431 | LCN2/S100A12 ratio | GCST90315309 | 24.96 |
| 432 | CCL5 levels | GCST90468584 | 24.88 |
| 433 | KIF22 levels | GCST90469682 | 24.85 |
| 434 | ALDH1A1/CA3 ratio | GCST90313244 | 24.85 |
| 435 | TNFSF12 levels | GCST90470919 | 24.84 |
| 436 | Qualifications - None of the above | Education | UKBB00000729 | 24.81 |
| 437 | Mean platelet thrombocyte volume (UKB data field 30100) | GCST90468087 | 24.79 |
| 438 | Lupus erythematosus | FING00000739 | 24.76 |
| 439 | S100A11/S100A12 ratio | GCST90315798 | 24.72 |
| 440 | red cell diameter width (RDW, minimum, inv-norm transformed) | GCST90476365 | 24.72 |
| 441 | CTF1/ITGB1BP2 ratio | GCST90314305 | 24.70 |
| 442 | Prostate cancer | GCST90274716 | 24.70 |
| 443 | Hypertension | circulatory system | UKBB00000334 | 24.65 |
| 444 | Ankle spacing width (left) | Bone-densitometry of heel | UKBB00000033 | 24.64 |
| 445 | Monocyte count | GCST90018747 | 24.63 |
| 446 | Frequency of drinking alcohol | Alcohol use | UKBB00000260 | 24.61 |
| 447 | TP53BP1 levels | GCST90470936 | 24.59 |
| 448 | TMSB10/TREML2 ratio | GCST90315923 | 24.58 |
| 449 | MAP4K5 levels | GCST90469855 | 24.57 |
| 450 | Essential hypertension | circulatory system | UKBB00000209 | 24.54 |
| 451 | PAPPA levels | GCST90470157 | 24.53 |
| 452 | IDP T1 FAST ROIs L cerebellum V | GCST90002564 | 24.50 |
| 453 | Ectopic pregnancy | FING00000487 | 24.48 |
| 454 | SDC4/SEMA4D ratio | GCST90315818 | 24.45 |
| 455 | T1 FreeSurfer a2009s rh S temporal sup volume | GCST90385110 | 24.43 |
| 456 | LZTFL1 levels | GCST90469834 | 24.43 |
| 457 | Mean corpuscular hemoglobin concentration | GCST90002391 | 24.42 |
| 458 | ATG4A/NSFL1C ratio | GCST90313368 | 24.38 |
| 459 | MAP2K6/TBL1X ratio | GCST90315378 | 24.32 |
| 460 | DCTD levels | GCST90468957 | 24.31 |
| 461 | TIMP3/ZBTB16 ratio | GCST90315921 | 24.28 |
| 462 | SERPINE1/SPARC ratio | GCST90315834 | 24.26 |
| 463 | Central pulse pressure | GCST90267387 | 24.21 |
| 464 | IPCEF1 levels | GCST90469624 | 24.12 |
| 465 | Nontoxic goitre/thyroid nodule | FING00000887 | 24.10 |
| 466 | Spread type: Butter and margarine spreads vs oil-based spreads (UKB data field 1428) | GCST90132951 | 24.09 |
| 467 | DSG3/FABP9 ratio | GCST90314559 | 23.98 |
| 468 | PDGFB/TNFSF13 ratio | GCST90315632 | 23.95 |
| 469 | CLEC1B/DKK1 ratio | GCST90314088 | 23.93 |
| 470 | CXCL1 levels | GCST90468930 | 23.92 |
| 471 | PF4 levels | GCST90470211 | 23.86 |
| 472 | Ankle spacing width (right) | Bone-densitometry of heel | UKBB00000034 | 23.82 |
| 473 | AXL/GAS6 ratio | GCST90313419 | 23.79 |
| 474 | PRG2 levels | GCST90470322 | 23.78 |
| 475 | FXN/TRIAP1 ratio | GCST90314899 | 23.75 |
| 476 | CETN3 levels | GCST90468722 | 23.73 |
| 477 | NUB1/SRPK2 ratio | GCST90315573 | 23.69 |
| 478 | SNAP25 levels | GCST90470691 | 23.68 |
| 479 | APRT/NSFL1C ratio | GCST90313337 | 23.68 |
| 480 | DCTN1/TRIAP1 ratio | GCST90314434 | 23.67 |
| 481 | PDGFB/TIMP3 ratio | GCST90315631 | 23.64 |
| 482 | CD84/DKK1 ratio | GCST90313911 | 23.63 |
| 483 | FHIT/MAX ratio | GCST90314818 | 23.63 |
| 484 | CSF3R levels | GCST90468885 | 23.57 |
| 485 | DIPK2B levels | GCST90468996 | 23.54 |
| 486 | PEAR1/SCARF1 ratio | GCST90315642 | 23.54 |
| 487 | CD40/TIMP3 ratio | GCST90313829 | 23.54 |
| 488 | ITPR1 levels | GCST90469655 | 23.48 |
| 489 | ANGPT1 levels | GCST90468300 | 23.38 |
| 490 | BSG/IL12A_IL12B ratio | GCST90313532 | 23.38 |
| 491 | DLL1/TGFBR2 ratio | GCST90314499 | 23.36 |
| 492 | Plasma X-24947 levels in chronic kidney disease | GCST90266816 | 23.29 |
| 493 | NOTCH1/SEMA7A ratio | GCST90315545 | 23.28 |
| 494 | Plasma 3-hydroxybutyroylglycine** levels in chronic kidney disease | GCST90264488 | 23.26 |
| 495 | Mineral and other dietary supplements - Calcium | Medication | UKBB00000471 | 23.26 |
| 496 | PSRC1 levels | GCST90470365 | 23.16 |
| 497 | Snoring | Sleep | UKBB00000784 | 23.15 |
| 498 | CD40LG/EDAR ratio | GCST90313818 | 23.11 |
| 499 | Neutrophil percentage of white cells | GCST90002399 | 23.08 |
| 500 | Blood cell traits latent factor 2 (red cell) | GCST90559244 | 23.03 |
| 501 | OTUD7B levels | GCST90470137 | 23.01 |
| 502 | TMSB10/TXNRD1 ratio | GCST90315925 | 22.98 |
| 503 | Basophil percentage of granulocytes | GCST004634 | 22.97 |
| 504 | Participation in an health questionnaire (not invited vs invited) | GCST90012794 | 22.95 |
| 505 | MTSS2 levels | GCST90469961 | 22.95 |
| 506 | Pain in joint | FING00001137 | 22.94 |
| 507 | DNA methylation Hannum age acceleration | GCST90014289 | 22.93 |
| 508 | EREG/TIMP3 ratio | GCST90314708 | 22.90 |
| 509 | BIRC2/CD40LG ratio | GCST90313517 | 22.89 |
| 510 | Red cell distribution width | GCST90025988 | 22.82 |
| 511 | DDAH1 levels | GCST90468966 | 22.82 |
| 512 | TREML1 levels | GCST90470961 | 22.80 |
| 513 | FUT8 levels | GCST90469281 | 22.80 |
| 514 | CST7 levels | GCST90468897 | 22.79 |
| 515 | FUT8/TNFSF12 ratio | GCST90314894 | 22.77 |
| 516 | Snoring | GCST009760 | 22.73 |
| 517 | Frailty (Factor 2 - Unhealthy Lifestyle) | GCST90624048 | 22.67 |
| 518 | PRKRA levels | GCST90470331 | 22.66 |
| 519 | DAB2 levels | GCST90468942 | 22.66 |
| 520 | SULT1A1 levels | GCST90470781 | 22.61 |
| 521 | Substance abuse (more control exclusions) | FING00001341 | 22.56 |
| 522 | Tonsillectomy and adenotomy | FING00001367 | 22.51 |
| 523 | Poultry consumption | GCST90132996 | 22.47 |
| 524 | Platelet count during postpartum period | GCST90302228 | 22.41 |
| 525 | FOXO1/MAP4K5 ratio | GCST90314872 | 22.39 |
| 526 | IRAK1/SPRY2 ratio | GCST90315196 | 22.32 |
| 527 | FAM13A levels | GCST90469181 | 22.32 |
| 528 | ANXA4/FADD ratio | GCST90313291 | 22.32 |
| 529 | FADD/GRAP2 ratio | GCST90314766 | 22.28 |
| 530 | TIMM10 levels | GCST90470867 | 22.24 |
| 531 | CXCL11/SDC4 ratio | GCST90314336 | 22.22 |
| 532 | NUDC levels | GCST90470102 | 22.18 |
| 533 | ENO2/MANF ratio | GCST90314662 | 22.16 |
| 534 | CA1/CA3 ratio | GCST90313572 | 22.15 |
| 535 | EDAR/TMSB10 ratio | GCST90314590 | 22.13 |
| 536 | PPBP levels | GCST90470289 | 22.07 |
| 537 | YTHDF3 levels | GCST90471091 | 22.06 |
| 538 | Sleep apnoea, including avohilmo | FING00001310 | 22.05 |
| 539 | DKK1/VTA1 ratio | GCST90314485 | 22.04 |
| 540 | DYNLT1 levels | GCST90469057 | 21.99 |
| 541 | IDP dMRI ProbtrackX ISOVF str l | GCST90004548 | 21.99 |
| 542 | TIA1 levels | GCST90470862 | 21.98 |
| 543 | EGLN1/PIK3AP1 ratio | GCST90314619 | 21.97 |
| 544 | Vascular/heart problems diagnosed by doctor - High blood pressure | Medical conditions | UKBB00000898 | 21.89 |
| 545 | Sedentary behavior at work | GCST90104345 | 21.89 |
| 546 | Osteoarthrosis, localized, primary (PheCode 740.11) | GCST90476255 | 21.88 |
| 547 | Time spent watching television (TV) | Physical activity | UKBB00000821 | 21.84 |
| 548 | RRM2B levels | GCST90470500 | 21.80 |
| 549 | PDGFB/UXS1 ratio | GCST90315634 | 21.76 |
| 550 | BCR/VASH1 ratio | GCST90313499 | 21.73 |
| 551 | FUT3_FUT5/LILRA2 ratio | GCST90314889 | 21.69 |
| 552 | ADAMTS4 levels | GCST90468226 | 21.67 |
| 553 | DAAM1 levels | GCST90468941 | 21.64 |
| 554 | Monocyte count | GCST90002341 | 21.63 |
| 555 | ENO2/SCRN1 ratio | GCST90314668 | 21.62 |
| 556 | White blood cell count | GCST004610 | 21.61 |
| 557 | CLEC1B/LBR ratio | GCST90314095 | 21.60 |
| 558 | Medication for pain relief, constipation, heartburn - Omeprazole (e.g. Zanprol) | Medication | UKBB00000458 | 21.60 |
| 559 | S100A4 levels | GCST90470518 | 21.49 |
| 560 | IDP dMRI ProbtrackX L1 slf r | GCST90004268 | 21.49 |
| 561 | Leg fat percentage right (UKB data field 23111) | GCST90468175 | 21.47 |
| 562 | DTD1 levels | GCST90469045 | 21.44 |
| 563 | EDAR/EGF ratio | GCST90314573 | 21.42 |
| 564 | Biological Mother: Cancer, Skin | GCST90475487 | 21.42 |
| 565 | Vitamin and mineral supplements - None of the above | Medication | UKBB00000901 | 21.39 |
| 566 | RILPL2 levels | GCST90470470 | 21.39 |
| 567 | IL15/NCR1 ratio | GCST90315150 | 21.39 |
| 568 | TACC3/TRIAP1 ratio | GCST90315901 | 21.38 |
| 569 | SPINT2/TNFSF13 ratio | GCST90315879 | 21.38 |
| 570 | CD69/EDAR ratio | GCST90313875 | 21.37 |
| 571 | PDLIM7 levels | GCST90470198 | 21.37 |
| 572 | Sleep apnea syndrome | GCST90267361 | 21.35 |
| 573 | Immature fraction of reticulocytes | GCST90002387 | 21.32 |
| 574 | MGLL/PTPN6 ratio | GCST90315440 | 21.26 |
| 575 | Types of transport used (excluding work) - Walk | Physical activity | UKBB00000879 | 21.25 |
| 576 | Lymphocyte percentage of white cells | GCST90002389 | 21.23 |
| 577 | GP1BA levels | GCST90469380 | 21.22 |
| 578 | AXIN1/DOK2 ratio | GCST90313406 | 21.21 |
| 579 | Conditional arithmetic | Fluid intelligence / reasoning | UKBB00000145 | 21.12 |
| 580 | Mental and behavioural disorders due to use of other stimulants, including caffeine | FING00000811 | 21.12 |
| 581 | METAP1D/PLXNA4 ratio | GCST90315427 | 21.10 |
| 582 | LAT2/YES1 ratio | GCST90315282 | 21.10 |
| 583 | Number of sexual partners in opposite-sex sexual behavior | GCST90026480 | 21.08 |
| 584 | WASF1 levels | GCST90471067 | 21.06 |
| 585 | Spleen volume | GCST90016667 | 21.06 |
| 586 | CCL5/CXCL3 ratio | GCST90313700 | 21.05 |
| 587 | CTF1 levels | GCST90468901 | 21.05 |
| 588 | APRT/EREG ratio | GCST90313335 | 20.99 |
| 589 | GFER/VASH1 ratio | GCST90314922 | 20.98 |
| 590 | HCLS1/TMSB10 ratio | GCST90315043 | 20.96 |
| 591 | MPIG6B levels | GCST90469935 | 20.96 |
| 592 | CRADD/EDAR ratio | GCST90314235 | 20.93 |
| 593 | CEP20 levels | GCST90468712 | 20.91 |
| 594 | CD302/IL12A_IL12B ratio | GCST90313806 | 20.89 |
| 595 | Current Smoker | FING00000371 | 20.87 |
| 596 | DAB2/GRAP2 ratio | GCST90314364 | 20.87 |
| 597 | Waist circumference (UKB data field 48) | GCST90468182 | 20.86 |
| 598 | Diffuse idiopathic skeletal hyperostosis flow score | GCST90134532 | 20.85 |
| 599 | GZMA/IL12A_IL12B ratio | GCST90315009 | 20.80 |
| 600 | ACOX1/VSIR ratio | GCST90313155 | 20.78 |
| 601 | RGS10 levels | GCST90470465 | 20.77 |
| 602 | SEPTIN8 levels | GCST90470578 | 20.76 |
| 603 | EIF4B levels | GCST90469094 | 20.75 |
| 604 | Severe, life-threatening illness (confirmatory factor analysis Factor 20) | GCST90309354 | 20.74 |
| 605 | CASP10 levels | GCST90468542 | 20.70 |
| 606 | SMAD3 levels | GCST90470677 | 20.68 |
| 607 | Alcohol usually taken with meals | Alcohol | UKBB00000025 | 20.64 |
| 608 | AXIN1/INPPL1 ratio | GCST90313410 | 20.63 |
| 609 | CEACAM6 levels | GCST90468697 | 20.61 |
| 610 | CA4/SELE ratio | GCST90313587 | 20.61 |
| 611 | APRT/MIF ratio | GCST90313336 | 20.60 |
| 612 | Blood cell traits latent factor 10 (platelet) | GCST90559252 | 20.59 |
| 613 | IDP dMRI TBSS ISOVF Anterior corona radiata L | GCST90004500 | 20.57 |
| 614 | ANGPT1/PDGFA ratio | GCST90313266 | 20.56 |
| 615 | IL2RA/NCR1 ratio | GCST90315161 | 20.56 |
| 616 | FKBP4 levels | GCST90469243 | 20.54 |
| 617 | aparc-a2009s lh area S-temporal-sup | GCST90003369 | 20.52 |
| 618 | Alcohol consumption | GCST90133003 | 20.51 |
| 619 | NUCB2 levels | GCST90470101 | 20.49 |
| 620 | Basophil count | GCST90002292 | 20.47 |
| 621 | Principal component-derived dietary pattern 8 | GCST90133013 | 20.40 |
| 622 | Prescriptions - metformin | biguanides,diabetes | UKBB00000692 | 20.40 |
| 623 | SH2D1A levels | GCST90470617 | 20.40 |
| 624 | Prescriptions - biguanides|diabetes | UKBB00000671 | 20.39 |
| 625 | BIN2/PDLIM7 ratio | GCST90313509 | 20.38 |
| 626 | rfMRI connectivity (ICA100 edge 995) | GCST90005848 | 20.33 |
| 627 | neutrophil (absolute count, minimum, inv-norm transformed) | GCST90475532 | 20.33 |
| 628 | ARHGEF1 levels | GCST90468359 | 20.24 |
| 629 | Basophil count | GCST90025997 | 20.23 |
| 630 | NCK2 levels | GCST90470007 | 20.21 |
| 631 | Hematocrit | GCST90002305 | 20.20 |
| 632 | GMFG levels | GCST90469366 | 20.20 |
| 633 | FKBP1B levels | GCST90469242 | 20.19 |
| 634 | CD40/CRELD2 ratio | GCST90313811 | 20.18 |
| 635 | Other embolism and thrombosis | FING00001043 | 20.16 |
| 636 | ACADSB levels | GCST90468195 | 20.16 |
| 637 | IDP dMRI ProbtrackX ICVF str r | GCST90004399 | 20.15 |
| 638 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 16) | GCST90320579 | 20.11 |
| 639 | Other arthrosis | FING00000965 | 20.10 |
| 640 | NUDT5 levels | GCST90470107 | 20.10 |
| 641 | Blood cell traits latent factor 5 (platelet) | GCST90559247 | 20.05 |
| 642 | CASP3/MESD ratio | GCST90313636 | 20.04 |
| 643 | ZFYVE19 levels | GCST90471098 | 20.00 |
| 644 | Right-hemisphere somatomotor network to putamen white-matter structural connectivity | GCST90302796 | 19.98 |
| 645 | EBI3_IL27/VCAM1 ratio | GCST90314572 | 19.97 |
| 646 | Leg predicted mass (left) | Impedance measures | UKBB00000396 | 19.96 |
| 647 | CD84/DAG1 ratio | GCST90313910 | 19.95 |
| 648 | MED18/SMAD1 ratio | GCST90315413 | 19.93 |
| 649 | Internal derangement of knee | injuries & poisonings | UKBB00000368 | 19.91 |
| 650 | AGRP/CCN1 ratio | GCST90313202 | 19.85 |
| 651 | LCN2/RETN ratio | GCST90315308 | 19.85 |
| 652 | YES1 levels | GCST90471088 | 19.82 |
| 653 | Neutrophill percentage (UKB data field 30200) | GCST90468093 | 19.82 |
| 654 | Patient classification on admission (recoded) - Inpatient | Summary Administration | UKBB00000637 | 19.76 |
| 655 | CXCL11/CXCL13 ratio | GCST90314333 | 19.75 |
| 656 | Non-cancer illness code, self-reported - hypertension | Medical conditions | UKBB00000517 | 19.72 |
| 657 | Gonarthrosis | FING00000585 | 19.72 |
| 658 | KIRREL2/PLA2G1B ratio | GCST90315251 | 19.68 |
| 659 | TNFSF14 levels | GCST90470922 | 19.68 |
| 660 | RARRES2/ST6GAL1 ratio | GCST90315759 | 19.67 |
| 661 | APP/VEGFC ratio | GCST90313333 | 19.67 |
| 662 | Leg fat-free mass (left) | Impedance measures | UKBB00000393 | 19.67 |
| 663 | Number of self-reported non-cancer illnesses | Medical conditions | UKBB00000541 | 19.66 |
| 664 | Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditions | UKBB00000369 | 19.62 |
| 665 | FLT1/VEGFA ratio | GCST90314858 | 19.61 |
| 666 | Basophil percentage of white cells | GCST90002380 | 19.61 |
| 667 | PTPRH levels | GCST90470382 | 19.55 |
| 668 | FKBP14 levels | GCST90469241 | 19.55 |
| 669 | AARSD1/PIK3AP1 ratio | GCST90313129 | 19.55 |
| 670 | Neutrophill count | Blood count | UKBB00000497 | 19.52 |
| 671 | TMSB10/TRIAP1 ratio | GCST90315924 | 19.49 |
| 672 | DNA methylation PhenoAge acceleration | GCST90014292 | 19.49 |
| 673 | MAP2K6 levels | GCST90469852 | 19.47 |
| 674 | CEP43/WASF1 ratio | GCST90314023 | 19.42 |
| 675 | Nerve, nerve root and plexus disorders | FING00000862 | 19.38 |
| 676 | EDAR/SNAP23 ratio | GCST90314587 | 19.37 |
| 677 | Total diffusion tensor imaging along the perivascular space index | GCST90455546 | 19.36 |
| 678 | DCTN1/ERBIN ratio | GCST90314429 | 19.34 |
| 679 | Leg fat-free mass (right) | Impedance measures | UKBB00000394 | 19.34 |
| 680 | CIAPIN1/SNAP29 ratio | GCST90314067 | 19.30 |
| 681 | DKK1/VEGFA ratio | GCST90314483 | 19.25 |
| 682 | ESYT2 levels | GCST90469156 | 19.24 |
| 683 | GHRL levels | GCST90469341 | 19.23 |
| 684 | Frequency of tiredness / lethargy in last 2 weeks | Mental health | UKBB00000268 | 19.22 |
| 685 | Number of days/week walked 10+ minutes | Physical activity | UKBB00000535 | 19.22 |
| 686 | CLEC1A/GPR37 ratio | GCST90314084 | 19.22 |
| 687 | CD69/CDKN2D ratio | GCST90313866 | 19.22 |
| 688 | F-sweetened coffee drink liking (derived food-liking factor) | GCST90094853 | 19.21 |
| 689 | APLP1 levels | GCST90468330 | 19.21 |
| 690 | CASP2 levels | GCST90468544 | 19.19 |
| 691 | FIS1 levels | GCST90469240 | 19.18 |
| 692 | CD40LG/EGF ratio | GCST90313819 | 19.18 |
| 693 | CEP43 levels | GCST90468715 | 19.17 |
| 694 | ESAM levels | GCST90469152 | 19.15 |
| 695 | Principal component-derived dietary pattern 30 | GCST90133035 | 19.14 |
| 696 | EDAR/SERPINB1 ratio | GCST90314586 | 19.14 |
| 697 | ENO2/TXNDC5 ratio | GCST90314671 | 19.14 |
| 698 | Neutrophill percentage | Blood count | UKBB00000498 | 19.13 |
| 699 | Monocyte count | Blood count | UKBB00000479 | 19.12 |
| 700 | TRIM5 levels | GCST90470970 | 19.08 |
| 701 | SH2B3/TBL1X ratio | GCST90315841 | 19.05 |
| 702 | GOLM2 levels | GCST90469376 | 19.04 |
| 703 | Ankle spacing width | Bone-densitometry of heel | UKBB00000035 | 19.03 |
| 704 | RAB2B levels | GCST90470406 | 18.97 |
| 705 | BMP6/SPINT2 ratio | GCST90313529 | 18.96 |
| 706 | PRAP1 levels | GCST90470312 | 18.87 |
| 707 | IMPA1 levels | GCST90469610 | 18.83 |
| 708 | Operative procedures - No procedure performed | Summary Operations | UKBB00000584 | 18.82 |
| 709 | Mood [affective] disorders | FING00000836 | 18.82 |
| 710 | Interpolated Year when non-cancer illness first diagnosed | Medical conditions | UKBB00000371 | 18.82 |
| 711 | Leg fat percentage (right) | Impedance measures | UKBB00000392 | 18.79 |
| 712 | Leg predicted mass (right) | Impedance measures | UKBB00000397 | 18.77 |
| 713 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 18.77 |
| 714 | GFER/TRIAP1 ratio | GCST90314921 | 18.76 |
| 715 | HNRNPK levels | GCST90469469 | 18.75 |
| 716 | Sleep apnea (MTAG) | GCST90267362 | 18.68 |
| 717 | CIAPIN1/PLA2G4A ratio | GCST90314065 | 18.65 |
| 718 | F2R levels | GCST90469168 | 18.60 |
| 719 | Ovarian dysfunction | FING00001133 | 18.59 |
| 720 | Osteitis deformans and osteopathies associated with other disorders classified elsewhere (PheCode 731) | GCST90476246 | 18.57 |
| 721 | Champagne or white wine consumption (glasses per month) (UKB data field 1578, 4418) | GCST90132986 | 18.57 |
| 722 | SNAP29/SNX9 ratio | GCST90315859 | 18.55 |
| 723 | Right-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302811 | 18.53 |
| 724 | Fresh fruit consumption | GCST90132979 | 18.52 |
| 725 | Forced vital capacity (FVC) | Spirometry | UKBB00000254 | 18.48 |
| 726 | Mean platelet volume during third trimester of pregnancy | GCST90302231 | 18.48 |
| 727 | RGMB/TNFRSF21 ratio | GCST90315772 | 18.47 |
| 728 | Septal defects | FING00001293 | 18.45 |
| 729 | ENO2 levels | GCST90469110 | 18.43 |
| 730 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 18.42 |
| 731 | DKK1/MGLL ratio | GCST90314473 | 18.41 |
| 732 | Age when finished full-time education (standard GWA) | GCST90267280 | 18.38 |
| 733 | FUT8/SORT1 ratio | GCST90314892 | 18.37 |
| 734 | Lymphocyte percentage | Blood count | UKBB00000412 | 18.36 |
| 735 | VASH1 levels | GCST90471026 | 18.35 |
| 736 | Red cell distribution width | GCST90002369 | 18.33 |
| 737 | Basophil count | GCST90002379 | 18.31 |
| 738 | Seminoma of testis, excluding all cancers (controls excluding all cancers) | FING00001289 | 18.31 |
| 739 | SCPEP1 levels | GCST90470553 | 18.30 |
| 740 | Usual walking pace | Physical activity | UKBB00000891 | 18.29 |
| 741 | Deep venous thrombosis | GCST90468122 | 18.29 |
| 742 | EGF levels | GCST90469086 | 18.26 |
| 743 | A1BG levels | GCST90468185 | 18.25 |
| 744 | CXCL11/ITGB1BP2 ratio | GCST90314335 | 18.24 |
| 745 | Basophill percentage | Blood count | UKBB00000087 | 18.19 |
| 746 | LATS1 levels | GCST90469740 | 18.19 |
| 747 | Volume of right cortical nucleus | GCST90474919 | 18.19 |
| 748 | SARG levels | GCST90470526 | 18.18 |
| 749 | Migraine, single triptan purchase ok & required. ICD-code if available is included | FING00000824 | 18.18 |
| 750 | POSTN levels | GCST90470288 | 18.14 |
| 751 | Any mental disorder | FING00000100 | 18.13 |
| 752 | BLOC1S3 levels | GCST90468450 | 18.08 |
| 753 | NSFL1C/PSMG3 ratio | GCST90315559 | 18.07 |
| 754 | Vitamin and mineral supplements - Multivitamins +/- minerals | Medication | UKBB00000900 | 18.07 |
| 755 | LYN levels | GCST90469826 | 18.05 |
| 756 | IGSF8/VSIR ratio | GCST90315141 | 18.05 |
| 757 | FKBP4/RWDD1 ratio | GCST90314840 | 18.04 |
| 758 | NCK2/PLA2G4A ratio | GCST90315524 | 18.01 |
| 759 | Treatment speciality of consultant (recoded) - General medicine | Summary Administration | UKBB00000832 | 18.01 |
| 760 | EREG levels | GCST90469145 | 18.01 |
| 761 | CST3/TIMP1 ratio | GCST90314300 | 17.98 |
| 762 | LCN2/PRTN3 ratio | GCST90315307 | 17.96 |
| 763 | CCN2/HBEGF ratio | GCST90313713 | 17.96 |
| 764 | COL5A1 levels | GCST90468820 | 17.95 |
| 765 | AGRP/NPY ratio | GCST90313203 | 17.92 |
| 766 | ITGA5/SELE ratio | GCST90315205 | 17.90 |
| 767 | Leg fat mass (right) | Impedance measures | UKBB00000390 | 17.89 |
| 768 | IL6ST/TYRO3 ratio | GCST90315170 | 17.88 |
| 769 | MGLL/PLA2G4A ratio | GCST90315439 | 17.88 |
| 770 | Follicular lymphoma, hilmo (controls excluding all cancers) | FING00000548 | 17.82 |
| 771 | Number of incorrect matches in round | Pairs matching | UKBB00000538 | 17.81 |
| 772 | DAB2/FKBP5 ratio | GCST90314363 | 17.81 |
| 773 | PCDH9 levels | GCST90470172 | 17.81 |
| 774 | ANXA3/ANXA4 ratio | GCST90313278 | 17.79 |
| 775 | PDGFA/SNAP23 ratio | GCST90315619 | 17.78 |
| 776 | MYDGF levels | GCST90469972 | 17.78 |
| 777 | ACVRL1/TNFRSF19 ratio | GCST90313159 | 17.77 |
| 778 | Whole grain cereal liking | GCST90094869 | 17.77 |
| 779 | rfMRI connectivity ICA-features 3 | GCST90006341 | 17.76 |
| 780 | MAVS/PPP1R9B ratio | GCST90315393 | 17.75 |
| 781 | BLVRB/CA1 ratio | GCST90313521 | 17.75 |
| 782 | Pyruvate levels (UKB data field 23472) | GCST90269569 | 17.75 |
| 783 | EBAG9/FKBP5 ratio | GCST90314564 | 17.74 |
| 784 | CD274/EFNA4 ratio | GCST90313768 | 17.73 |
| 785 | DFFA levels | GCST90468987 | 17.73 |
| 786 | CASP3 levels | GCST90468545 | 17.67 |
| 787 | Left-hemisphere limbic network to thalamus white-matter structural connectivity | GCST90302736 | 17.65 |
| 788 | LGALS1 levels | GCST90469759 | 17.65 |
| 789 | PEAR1/TREML2 ratio | GCST90315645 | 17.61 |
| 790 | Arterial embolism and thrombosis of lower extremity artery | FING00000106 | 17.60 |
| 791 | Treatment or medication use - insulin product (UKB data field 20003_1140883066) | GCST90042226 | 17.59 |
| 792 | ADGRF5 levels | GCST90468239 | 17.58 |
| 793 | CC2D1A/TMSB10 ratio | GCST90313667 | 17.56 |
| 794 | MTHFSD levels | GCST90469956 | 17.55 |
| 795 | ANXA3/EDAR ratio | GCST90313280 | 17.55 |
| 796 | Chronic sinusitis (PheCode 475) | GCST90476020 | 17.52 |
| 797 | Acquired foot deformities (PheCode 735) | GCST90476247 | 17.51 |
| 798 | Red cell distribution width | GCST90002404 | 17.50 |
| 799 | Red blood cell (erythrocyte) distribution width | Blood count | UKBB00000748 | 17.49 |
| 800 | FADD/PPP1R2 ratio | GCST90314774 | 17.49 |
| 801 | Alcohol drinker status - Current | Alcohol | UKBB00000021 | 17.48 |
| 802 | Alcohol abuse, main dg (more control exclusions) | FING00000049 | 17.47 |
| 803 | CCL17/CD69 ratio | GCST90313684 | 17.46 |
| 804 | CXCL5/MESD ratio | GCST90314350 | 17.45 |
| 805 | X-24337 levels | GCST90200629 | 17.44 |
| 806 | CHRDL1/SMOC2 ratio | GCST90314062 | 17.44 |
| 807 | CD84/VASH1 ratio | GCST90313920 | 17.43 |
| 808 | CEP43/TIA1 ratio | GCST90314021 | 17.43 |
| 809 | F-healthy food liking (derived food-liking factor) | GCST90094779 | 17.41 |
| 810 | Tea without sugar liking | GCST90094858 | 17.39 |
| 811 | PHLDB1 levels | GCST90470225 | 17.39 |
| 812 | FLI1 levels | GCST90469247 | 17.39 |
| 813 | Annual healthcare cost | GCST90292604 | 17.33 |
| 814 | Hemoglobin | GCST90018737 | 17.32 |
| 815 | SIAE levels | GCST90470629 | 17.32 |
| 816 | PCDH12 levels | GCST90470168 | 17.31 |
| 817 | GFRA2/IL12A_IL12B ratio | GCST90314925 | 17.30 |
| 818 | SCARF1/TNFRSF14 ratio | GCST90315812 | 17.29 |
| 819 | Spicy food liking | GCST90094846 | 17.28 |
| 820 | DAG1/DKK1 ratio | GCST90314373 | 17.26 |
| 821 | FCER2/TREML2 ratio | GCST90314792 | 17.24 |
| 822 | Red blood cell erythrocyte distribution width (UKB data field 30070) | GCST90468099 | 17.23 |
| 823 | TXNDC5 levels | GCST90470991 | 17.21 |
| 824 | PSTPIP2 levels | GCST90470366 | 17.20 |
| 825 | FCAR levels | GCST90469197 | 17.13 |
| 826 | TAB2 levels | GCST90470796 | 17.12 |
| 827 | CA2/NSFL1C ratio | GCST90313580 | 17.12 |
| 828 | RILP/RWDD1 ratio | GCST90315778 | 17.10 |
| 829 | PDGFB/VEGFC ratio | GCST90315635 | 17.10 |
| 830 | Chronic airway obstruction (PheCode 496) | GCST90476027 | 17.09 |
| 831 | METAP1D levels | GCST90469892 | 17.08 |
| 832 | PTPRC levels | GCST90470380 | 17.06 |
| 833 | aparc-Desikan rh area isthmuscingulate | GCST90003116 | 17.06 |
| 834 | Acid reflux/GERD | GCST90475320 | 17.05 |
| 835 | EGLN1/PSIP1 ratio | GCST90314620 | 17.02 |
| 836 | Destinations on discharge from hospital (recoded) - Usual Place of residence | Summary Administration | UKBB00000167 | 17.01 |
| 837 | CD38/IL12A_IL12B ratio | GCST90313808 | 17.01 |
| 838 | Acute appendicitis, with complications | FING00000019 | 17.00 |
| 839 | CA3 levels | GCST90468512 | 17.00 |
| 840 | CCN2/ENO2 ratio | GCST90313712 | 16.98 |
| 841 | Use of hypnotics and sedatives | FING00001411 | 16.97 |
| 842 | FADD/NCK2 ratio | GCST90314770 | 16.96 |
| 843 | EDAR/ENO2 ratio | GCST90314574 | 16.96 |
| 844 | CACNB3 levels | GCST90468523 | 16.94 |
| 845 | MAPKAPK2 levels | GCST90469858 | 16.92 |
| 846 | Bread type - White | Diet | UKBB00000106 | 16.90 |
| 847 | Thyrotoxicosis with toxic multinodular goitre | FING00001362 | 16.89 |
| 848 | CA1/TGM2 ratio | GCST90313575 | 16.89 |
| 849 | Cerebrospinal fluid 3-hydroxyhexanoate levels | GCST90318108 | 16.87 |
| 850 | RRM2B/SMAD1 ratio | GCST90315788 | 16.87 |
| 851 | monocyte (absolute count, mean, inv-norm transformed) | GCST90475502 | 16.86 |
| 852 | CREG1/NAAA ratio | GCST90314250 | 16.84 |
| 853 | Average weekly beer plus cider intake | Alcohol | UKBB00000082 | 16.81 |
| 854 | Percentage of invited food questionnaires completed | GCST90012790 | 16.81 |
| 855 | DKK1/VASH1 ratio | GCST90314482 | 16.80 |
| 856 | red cell diameter width (RDW, maximum, inv-norm transformed) | GCST90476357 | 16.78 |
| 857 | Drinks usually with meals in current drinkers (yes vs no) (UKB data field 1618) | GCST90132926 | 16.77 |
| 858 | GADD45GIP1 levels | GCST90469293 | 16.77 |
| 859 | CLEC1B/SORT1 ratio | GCST90314104 | 16.75 |
| 860 | Methods of discharge from hospital (recoded) - Discharged on clinical advice/consent | Summary Administration | UKBB00000466 | 16.74 |
| 861 | Frailty (Factor 1 - Limited Social Support) | GCST90624047 | 16.71 |
| 862 | MANF levels | GCST90469846 | 16.70 |
| 863 | CD69/CLEC1B ratio | GCST90313869 | 16.70 |
| 864 | F-healthy breakfast food liking (derived food-liking factor) | GCST90094780 | 16.70 |
| 865 | aparc-a2009s rh volume S-subparietal | GCST90003069 | 16.68 |
| 866 | Fluid intelligence score decline (difference score) | GCST90565862 | 16.66 |
| 867 | IGF2R/LGMN ratio | GCST90315131 | 16.65 |
| 868 | ENO2/TACC3 ratio | GCST90314670 | 16.65 |
| 869 | THBS2 levels | GCST90470854 | 16.62 |
| 870 | CMC1 levels | GCST90468794 | 16.61 |
| 871 | PPP1R14D levels | GCST90470303 | 16.61 |
| 872 | NT5C3A levels | GCST90470091 | 16.61 |
| 873 | Prostate cancer | GCST90018685 | 16.60 |
| 874 | NAA80 levels | GCST90469990 | 16.59 |
| 875 | CEACAM8 levels | GCST90468698 | 16.57 |
| 876 | T1 CAT GM unnormalised volume | GCST90383982 | 16.55 |
| 877 | Occupational attainment | GCST90102253 | 16.55 |
| 878 | CD69/PLXNB3 ratio | GCST90313881 | 16.54 |
| 879 | Operative procedures - Endoscopic resection of semilunar cartilage NEC | Summary Operations | UKBB00000577 | 16.51 |
| 880 | CD40LG/SERPINE1 ratio | GCST90313826 | 16.50 |
| 881 | BCL2L1 levels | GCST90468432 | 16.49 |
| 882 | CCL17/THPO ratio | GCST90313689 | 16.49 |
| 883 | CLEC1B/DIABLO ratio | GCST90314087 | 16.48 |
| 884 | Medication for pain relief, constipation, heartburn - None of the above | Medication | UKBB00000457 | 16.48 |
| 885 | Leg fat percentage left (UKB data field 23115) | GCST90468174 | 16.48 |
| 886 | ASRGL1 levels | GCST90468379 | 16.47 |
| 887 | BCL2L11/VASH1 ratio | GCST90313485 | 16.47 |
| 888 | Waist circumference | Body size measures | UKBB00000904 | 16.46 |
| 889 | aparc-a2009s rh area G-precuneus | GCST90003400 | 16.46 |
| 890 | Nontoxic multinodular goitre | FING00000888 | 16.45 |
| 891 | RAB27B levels | GCST90470405 | 16.45 |
| 892 | DBNL/EDAR ratio | GCST90314416 | 16.45 |
| 893 | Weight | Impedance measures | UKBB00000910 | 16.44 |
| 894 | ERP29 levels | GCST90469149 | 16.44 |
| 895 | EREG/ITGB1BP2 ratio | GCST90314703 | 16.44 |
| 896 | Other diseases of intestines | FING00001001 | 16.44 |
| 897 | neutrophil (fraction, minimum, inv-norm transformed) | GCST90475541 | 16.44 |
| 898 | F11R levels | GCST90469164 | 16.42 |
| 899 | Number of treatments/medications taken | Medications | UKBB00000542 | 16.38 |
| 900 | Forced expiratory volume in 1-second (FEV1) | Spirometry | UKBB00000251 | 16.38 |
| 901 | GMPR levels | GCST90469368 | 16.38 |
| 902 | IDP dMRI ProbtrackX ISOVF ilf l | GCST90004539 | 16.36 |
| 903 | ATP5IF1/FXN ratio | GCST90313386 | 16.35 |
| 904 | GRAP2/PLPBP ratio | GCST90314984 | 16.32 |
| 905 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90024197 | 16.32 |
| 906 | CD69/CHMP1A ratio | GCST90313868 | 16.31 |
| 907 | CCL5/SELP ratio | GCST90313705 | 16.30 |
| 908 | GP6 levels | GCST90469384 | 16.30 |
| 909 | METAP2 levels | GCST90469894 | 16.28 |
| 910 | Enthesopathies of lower limb, excluding foot | FING00000509 | 16.28 |
| 911 | APRT/PSME1 ratio | GCST90313338 | 16.26 |
| 912 | T1 FreeSurfer DK rh fusiform volume | GCST90385763 | 16.26 |
| 913 | Deep vein thrombosis [DVT] (PheCode 452.2) | GCST90476010 | 16.23 |
| 914 | INSL4 levels | GCST90469621 | 16.22 |
| 915 | Paradoxical eczema in biologic-treated plaque psoriasis | GCST90162550 | 16.21 |
| 916 | NFATC1 levels | GCST90470033 | 16.18 |
| 917 | CD79B/ICAM3 ratio | GCST90313901 | 16.18 |
| 918 | White blood cell count | GCST90002374 | 16.17 |
| 919 | GIPC2 levels | GCST90469347 | 16.13 |
| 920 | SNX9/STIP1 ratio | GCST90315864 | 16.09 |
| 921 | Comparative height size at age 10 | Early life factors | UKBB00000143 | 16.09 |
| 922 | Frailty index | GCST90020053 | 16.08 |
| 923 | PFKM levels | GCST90618802 | 16.08 |
| 924 | BCAM/ICAM4 ratio | GCST90313472 | 16.07 |
| 925 | Substance use, excluding alcohol | FING00001342 | 16.06 |
| 926 | CCN2/MGLL ratio | GCST90313714 | 16.05 |
| 927 | IL31RA levels | GCST90469589 | 16.05 |
| 928 | FUT8/VEGFC ratio | GCST90314896 | 16.03 |
| 929 | Forced expiratory volume (baseline) | GCST90565844 | 16.02 |
| 930 | CDC26 levels | GCST90468663 | 16.01 |
| 931 | Essential tremor (PheCode 333.1) | GCST90475832 | 16.01 |
| 932 | EDAR/TACC3 ratio | GCST90314589 | 15.97 |
| 933 | VSTM1 levels | GCST90471055 | 15.96 |
| 934 | PSME1 levels | GCST90470360 | 15.95 |
| 935 | Other dyspnea (PheCode 512.9) | GCST90476042 | 15.94 |
| 936 | Chronic bronchitis (PheCode 496.2) | GCST90476029 | 15.90 |
| 937 | MED18/ZBTB16 ratio | GCST90315416 | 15.90 |
| 938 | Arthrosis | FING00000111 | 15.90 |
| 939 | CD40/TNFRSF14 ratio | GCST90313830 | 15.89 |
| 940 | CD38/RELT ratio | GCST90313809 | 15.88 |
| 941 | Irregular menses | FING00000701 | 15.85 |
| 942 | Arm fat percentage (left) | Impedance measures | UKBB00000045 | 15.84 |
| 943 | Red blood cell count | GCST90278641 | 15.81 |
| 944 | CLEC4C levels | GCST90468772 | 15.81 |
| 945 | Trigger finger | FING00001376 | 15.81 |
| 946 | CD22/FOLR2 ratio | GCST90313758 | 15.79 |
| 947 | SRPK2 levels | GCST90470743 | 15.78 |
| 948 | NUDT5/TXNRD1 ratio | GCST90315582 | 15.78 |
| 949 | Takes medication for Diabetes/sugar? | GCST90475268 | 15.78 |
| 950 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T498 | ECGA000498 | 15.74 |
| 951 | INSL5 levels | GCST90469622 | 15.73 |
| 952 | CD63 levels | GCST90468642 | 15.72 |
| 953 | AXIN1/CALCOCO1 ratio | GCST90313402 | 15.72 |
| 954 | DRAXIN levels | GCST90469038 | 15.72 |
| 955 | SNAP23 levels | GCST90470690 | 15.70 |
| 956 | AARSD1/UBAC1 ratio | GCST90313135 | 15.69 |
| 957 | Immature fraction of reticulocytes | GCST90025971 | 15.69 |
| 958 | PLIN3 levels | GCST90470259 | 15.68 |
| 959 | Trunk fat mass | Impedance measures | UKBB00000863 | 15.67 |
| 960 | SUSD1 levels | GCST90470786 | 15.67 |
| 961 | Weight | Body size measures | UKBB00000909 | 15.64 |
| 962 | Other cataract | Disorders of lens | UKBB00000602 | 15.64 |
| 963 | LAT/SPARC ratio | GCST90315288 | 15.63 |
| 964 | ABHD14B/SCRN1 ratio | GCST90313145 | 15.62 |
| 965 | IDP dMRI ProbtrackX ISOVF ilf r | GCST90004540 | 15.59 |
| 966 | CASP3/SERPINE1 ratio | GCST90313643 | 15.58 |
| 967 | BCR/ITGB1BP2 ratio | GCST90313494 | 15.58 |
| 968 | FGR/LBR ratio | GCST90314814 | 15.55 |
| 969 | Body size (confirmatory factor analysis Factor 21) | GCST90309355 | 15.53 |
| 970 | BPIFB2 levels | GCST90468463 | 15.52 |
| 971 | LGALS8/TXNDC5 ratio | GCST90315321 | 15.52 |
| 972 | Clonal hematopoiesis (DNMT3A mutation) | GCST90435354 | 15.50 |
| 973 | Other peripheral nerve disorders (PheCode 351) | GCST90475842 | 15.46 |
| 974 | CD38 levels | GCST90468628 | 15.46 |
| 975 | Artrosis, including avohilmo | FING00000112 | 15.45 |
| 976 | Duration walking for pleasure | Physical activity | UKBB00000203 | 15.45 |
| 977 | NSFL1C levels | GCST90470089 | 15.44 |
| 978 | Right-hemisphere dorsal attention network to right-hemisphere default mode network white-matter structural connectivity | GCST90302805 | 15.44 |
| 979 | EDAR/TXNDC5 ratio | GCST90314593 | 15.44 |
| 980 | TACC3/TBC1D23 ratio | GCST90315900 | 15.42 |
| 981 | SNAP29/SPARC ratio | GCST90315860 | 15.42 |
| 982 | DAG1/HBEGF ratio | GCST90314376 | 15.42 |
| 983 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 15.41 |
| 984 | LEP levels | GCST90469757 | 15.39 |
| 985 | neutrophil (fraction, mean, inv-norm transformed) | GCST90475538 | 15.39 |
| 986 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 15.39 |
| 987 | PPP1R2/TACC3 ratio | GCST90315719 | 15.38 |
| 988 | WFDC1 levels | GCST90471074 | 15.37 |
| 989 | MPHOSPH8/PSRC1 ratio | GCST90315478 | 15.37 |
| 990 | Other and/or unspecified nontoxic goitre | FING00000958 | 15.37 |
| 991 | GFER levels | GCST90469326 | 15.34 |
| 992 | Types of physical activity in last 4 weeks - Walking for pleasure (not as a means of transport) | Physical activity | UKBB00000875 | 15.34 |
| 993 | ATP5IF1/F2R ratio | GCST90313384 | 15.33 |
| 994 | NAAA/SMPD1 ratio | GCST90315510 | 15.33 |
| 995 | MTIF3 levels | GCST90469957 | 15.33 |
| 996 | Invitation to complete online 24-hour recall dietary questionnaire, acceptance | Online follow-up - Diet by 24-hour recall | UKBB00000378 | 15.31 |
| 997 | OSM/TGFA ratio | GCST90315590 | 15.29 |
| 998 | Right-hemisphere somatomotor network to hippocampus white-matter structural connectivity | GCST90302798 | 15.28 |
| 999 | Operative procedures - Insertion of prosthetic replacement for lens NEC | Summary Operations | UKBB00000583 | 15.28 |
| 1000 | Sleep apnea (MTAG) (adjusted for BMI) | GCST90267364 | 15.27 |